Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Zest Meds is more than just a healthcare provider; it’s a partner in your weight loss journey. Specializing in cutting-edge treatments like Semaglutide and Tirzepatide, Zest Meds has positioned ...
Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...
GEMMA Collins has revealed that she’s dropped two dress sizes after turning to fat loss injections. The TV favourite, 43, who ...
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...
Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...